2 of 3 Leading COVID-19 Vaccine Initiatives utilizing Generis’s Life Science Platform, CARA

Summation

  • Generis, the global leader in content information management systems, is proud to announce that two out of the three leading COVID-19 vaccine initiatives in Operation Warp Speed are using the CARA Life Science Platform for Regulatory.
  • “We proud of how swiftly Generis has reacted to help the Life Sciences and Healthcare industries throughout the COVID-19 crisis, eliminating fees and barriers to entry for critical or pioneering initiatives”, added James Kelleher.
  • That tangible impact on the future of our societies, economies, and personal wellbeing is something that Generis is extremely proud of.

Generis, the global leader in content information management systems, is proud to announce that two out of the three leading COVID-19 vaccine initiatives in Operation Warp Speed are using the CARA Life Science Platform for Regulatory.

Generis reports the US-driven international initiative to support the rapid development, manufacturing, and distribution of COVID-19 vaccines is progressing with many promising efforts to move towards Phase 3 clinical trials. The CARA Life Sciences Platform, provided by Generis, is helping these Life Science companies to greatly reduce their development and submission cycles while focusing on oversight and compliance with stringent health regulations.

James Kelleher, CEO, Generis commented: “We estimate that around 262,500 users of our CARA Life Sciences Platform are currently working on COVID-19 vaccines or treatments globally. That tangible impact on the future of our societies, economies, and personal wellbeing is something that Generis is extremely proud of. We know and appreciate that every effort from our developers, consulting, support and training teams, as well as industry leaders, will have a profound impact in saving and improving human life.”

The CARA Life Sciences Platform manages regulated business processes, managing content and data across the core functional areas of Life Science companies. Adoption of this platform has driven process efficiency improvements of up to 450%*, greatly reducing time-to-market for regulated products.

“We proud of how swiftly Generis has reacted to help the Life Sciences and Healthcare industries throughout the COVID-19 crisis, eliminating fees and barriers to entry for critical or pioneering initiatives”, added James Kelleher.

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy